Literature DB >> 22044596

Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop.

S R Selvaraj1, A N Scheller, H Z Miao, R J Kaufman, Steven W Pipe.   

Abstract

BACKGROUND: Heterologous expression of factor VIII (FVIII) is about two to three orders of magnitude lower than similarly sized proteins. Bioengineering strategies aimed at different structural and biochemical attributes of FVIII have been successful in enhancing its expression levels.
OBJECTIVE: Disulfide bonds are vital to the proper folding, secretion and stability of most secretory proteins. In an effort to explore additional targeted bioengineering approaches, the role of disulfide bonds in FVIII secretion and function was probed in this study. METHODS AND
RESULTS: Single and paired cysteine mutants were generated by substituting with serine or glycine residues and analyzed by transient transfection into COS-1 and CHO cells. Seven of the eight disulfide bonds in FVIII were found to be indispensable for proper secretion and function. However, elimination of the disulfide bond formed by C1899 and C1903 within the conserved A3 domain improved the secretion of FVIII. The addition of the C1899G/C1903G mutations to a previously described FVIII variant, 226/N6, with high secretion efficiency increased its secretion by 2.2-fold. Finally, the addition of the A1-domain mutation, F309S, in conjunction with the disulfide mutation had an additive effect, resulting in a net improvement in secretion of between 35 and 45-fold higher than wild-type FVIII in CHO cells.
CONCLUSION: Such combined targeted bioengineering strategies may facilitate more efficient production of recombinant FVIII and contribute toward low-cost factor replacement therapy for hemophilia A.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22044596      PMCID: PMC3290727          DOI: 10.1111/j.1538-7836.2011.04545.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  37 in total

1.  Evidence for difference in the roles of two cysteine residues involved in disulfide bond formation in the folding of human lysozyme.

Authors:  Y Taniyama; Y Yamamoto; R Kuroki; M Kikuchi
Journal:  J Biol Chem       Date:  1990-05-05       Impact factor: 5.157

2.  Elimination of disulfide bonds affects assembly and secretion of the human chorionic gonadotropin beta subunit.

Authors:  N Suganuma; M M Matzuk; I Boime
Journal:  J Biol Chem       Date:  1989-11-15       Impact factor: 5.157

3.  A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.

Authors:  J J Toole; D D Pittman; E C Orr; P Murtha; L C Wasley; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

4.  Protein dissociation from GRP78 and secretion are blocked by depletion of cellular ATP levels.

Authors:  A J Dorner; L C Wasley; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  Increased synthesis of secreted proteins induces expression of glucose-regulated proteins in butyrate-treated Chinese hamster ovary cells.

Authors:  A J Dorner; L C Wasley; R J Kaufman
Journal:  J Biol Chem       Date:  1989-12-05       Impact factor: 5.157

6.  High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1alpha gene.

Authors:  Jennifer Running Deer; Daniel S Allison
Journal:  Biotechnol Prog       Date:  2004 May-Jun

7.  Role of disulfide bonds in folding and secretion of human lysozyme in Saccharomyces cerevisiae.

Authors:  Y Taniyama; Y Yamamoto; M Nakao; M Kikuchi; M Ikehara
Journal:  Biochem Biophys Res Commun       Date:  1988-05-16       Impact factor: 3.575

8.  Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells.

Authors:  R J Kaufman; L C Wasley; M V Davies; R J Wise; D I Israel; A J Dorner
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

9.  Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.

Authors:  R J Kaufman; L C Wasley; A J Dorner
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

10.  The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins.

Authors:  A J Dorner; D G Bole; R J Kaufman
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

View more
  10 in total

1.  Effect of transmembrane pressure on Factor VIII yield in ATF perfusion culture for the production of recombinant human Factor VIII co-expressed with von Willebrand factor.

Authors:  Seung-Chul Kim; Sora An; Hyun-Ki Kim; Beom-Soo Park; Kyu-Heum Na; Byung-Gee Kim
Journal:  Cytotechnology       Date:  2015-10-13       Impact factor: 2.058

Review 2.  Platelet and endothelial expression of clotting factors for the treatment of hemophilia.

Authors:  Robert R Montgomery; Qizhen Shi
Journal:  Thromb Res       Date:  2012-03-14       Impact factor: 3.944

3.  FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.

Authors:  Simone Merlin; Rosella Famà; Ester Borroni; Diego Zanolini; Valentina Bruscaggin; Silvia Zucchelli; Antonia Follenzi
Journal:  Blood Adv       Date:  2019-03-12

4.  Factor VIIIa A2 subunit shows a high affinity interaction with factor IXa: contribution of A2 subunit residues 707-714 to the interaction with factor IXa.

Authors:  Amy E Griffiths; Ivan Rydkin; Philip J Fay
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

Review 5.  Engineering cells to improve protein expression.

Authors:  Su Xiao; Joseph Shiloach; Michael J Betenbaugh
Journal:  Curr Opin Struct Biol       Date:  2014-04-03       Impact factor: 6.809

6.  A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.

Authors:  Simone Merlin; Elvira Stefania Cannizzo; Ester Borroni; Valentina Bruscaggin; Piercarla Schinco; Warut Tulalamba; Marinee K Chuah; Valder R Arruda; Thierry VandenDriessche; Maria Prat; Guido Valente; Antonia Follenzi
Journal:  Mol Ther       Date:  2017-05-26       Impact factor: 11.454

7.  Upregulation of the coagulation factor VII gene during glucose deprivation is mediated by activating transcription factor 4.

Authors:  Katherine R Cronin; Thomas P Mangan; Josephine A Carew
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

8.  Development and characterization of recombinant ovine coagulation factor VIII.

Authors:  Philip M Zakas; Bagirath Gangadharan; Graca Almeida-Porada; Christopher D Porada; H Trent Spencer; Christopher B Doering
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

9.  Blood Clotting Factor VIII: From Evolution to Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

Review 10.  Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.

Authors:  Benjamin J Samelson-Jones; Valder R Arruda
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-31       Impact factor: 6.698

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.